Illumina (ILMN) Q4 2025 earnings review
Growth Returns, Margins Expand
Illumina has officially turned the corner. After three quarters of contraction or stagnation, Q4 revenue grew 5% YoY to $1.16B. The recovery is even stronger excluding China, where revenue surged 8%. Management's 'disciplined execution' is visible in the bottom line: Non-GAAP Operating Margin jumped 400 basis points to 23.7%. Guidance for FY26 forecasts continued acceleration (4-6% revenue growth) despite the dilutive impact of the newly closed SomaLogic acquisition.
🐂 Bull Case
The core business is healthier than the headline numbers suggest. Excluding China, revenue grew 8% YoY in Q4, signaling that the clinical market adoption of NGS testing is accelerating enough to overcome research budget constraints.
Cost cutting is working. Non-GAAP operating margin expanded from 19.7% in 24Q4 to 23.7% in 25Q4. This leverage drove a 42% YoY increase in Non-GAAP EPS ($1.35 vs $0.95), proving the company can grow earnings faster than sales.
🐻 Bear Case
The SomaLogic acquisition is a drag on near-term financials. FY26 guidance includes a 100bps hit to operating margin and $0.18 dilution to EPS. Integration risks now loom over the next 12 months.
While the export ban on sequencers was lifted, Illumina remains on the 'Unreliable Entities List.' The divergence between Total Revenue growth (+5%) and Ex-China growth (+8%) implies the China business continues to shrink or stagnate.
⚖️ Verdict: 🟢
Bullish. Illumina demonstrated a clean break from its recent slump. Revenue growth has returned, margins are expanding rapidly, and the FY26 outlook suggests stability. The China risk is now ring-fenced, allowing the ex-China clinical story to drive the stock.
Key Themes
Clinical Market Strength
Clinical adoption is the engine pulling the train. Ex-China revenue accelerated to +8% growth in Q4 (up from +2% in Q3), validating the thesis that clinical demand for sequencing (Oncology, Genetic Disease) is decoupling from the softer research environment.
Operational Efficiency
Management has successfully reset the cost base. Q4 Non-GAAP operating expenses dropped to $264M from $271M a year ago, even as revenue rose. This discipline allowed operating profit to surge 26% YoY ($275M vs $218M), creating a buffer for future investments.
Multiomics Expansion (SomaLogic)
The SomaLogic acquisition is closed, formally moving Illumina into proteomics. While strategically sound (connecting DNA to proteins), it financially weighs on FY26: accounting for a 1.5-2.0% revenue benefit but dragging margins down by 100 basis points.
China Regulatory Limbo
Progress is mixed. The Ministry of Commerce lifted the export ban on sequencers, a positive step. However, Illumina remains on the 'Unreliable Entities List' (UEL), requiring approvals for instrument purchases. This persistent uncertainty keeps the region as a growth headwind.
Research Funding Environment
While not explicitly detailed in the PR, the reliance on Clinical for growth implies the Research market remains muted. FY26 guidance for 'Ex-China Organic revenue growth' of only 2-4% suggests the academic/government funding environment is not expected to snap back aggressively.
Other KPIs
Beat significantly vs prior year ($0.95). Driven by higher revenue leverage and lower SG&A (-$7M YoY). The GAAP EPS of $2.16 included large one-time tax benefits and strategic investment gains, distorting the headline number.
Down slightly from $322M in 24Q4, but robust. Full year FCF was $931M. The company ended the year with a fortress balance sheet: $1.63B in cash and short-term investments, up from $1.13B a year ago, providing ample dry powder.
Lower than the 23.6% rate in FY24, aiding the EPS growth story. However, Q4 tax rate was exceptionally low at 19.5%.
Guidance
Accelerating. Represents 4-6% reported growth vs flat in FY25. Note that ~1.5-2.0% of this growth comes from the SomaLogic acquisition; organic ex-China growth is guided at 2-4%.
Accelerating. Implies ~4-7% growth over FY25's $4.84. This includes a $0.18 per share drag from SomaLogic. The underlying earnings power is stronger than the headline indicates.
Stable. Roughly flat vs FY25's 23.1%. This guidance absorbs a 100 basis point hit from SomaLogic. Excluding the acquisition, margins would be expanding toward ~24.5%, continuing the efficiency trend.
Key Questions
China UEL Resolution
With the export ban lifted, what specific milestones remain to be removed from the Unreliable Entities List, and does FY26 guidance assume any normalization of instrument sales in the region?
SomaLogic Synergies
Beyond the $0.18 EPS dilution in FY26, what is the timeline for the acquisition to become accretive, and are there immediate cross-selling opportunities with the NovaSeq X installed base?
Clinical vs Research Split
Q4 Ex-China revenue grew 8%. Can you break down the contribution of Clinical versus Research? Are we finally seeing a stabilization in the academic/government funding environment?
Service Revenue Decline
Q4 Service and Other revenue appears to have softened slightly or stayed flat relative to Product revenue gains. Is this a strategic shift away from lower-margin partnerships, or a demand signal?